Upper Tract Urothelial Cancer Treatment Granted Priority Review – Renal and Urology News
In a phase 3 trial, mitomycin gel for instillation showed a complete response rate of 59% of patients with low-grade upper tract urothelial cancer.
Related Articles
2024 FDA approvals
Nature Reviews Drug Discovery – The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine…
2024 FDA approvals
Nature Reviews Drug Discovery – The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine…
2024 FDA approvals
Nature Reviews Drug Discovery – The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine…
2024 FDA approvals
Nature Reviews Drug Discovery – The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine…
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Nature – Whole-genome sequencing of matched serial tumours from patients identifies two key mutagenic factors (APOBEC3 and chemotherapy) and extrachromosomal DNA-forming structural variants that…
Circumventing Cancer Resistance
Traditional and new cancer therapies often become stymied due to tumor resistance, but why resistance arises and how to avoid it remain important questions in…
Decoding aging clocks: New insights from metabolomics
Huang et al. conducted a comprehensive review of the literature on metabolomic aging clocks. They particularly emphasized how metabolomic aging clocks, as a novel tool for…
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Nature – Whole-genome sequencing of matched serial tumours from patients identifies two key mutagenic factors (APOBEC3 and chemotherapy) and extrachromosomal DNA-forming structural variants that…
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Nature – Whole-genome sequencing of matched serial tumours from patients identifies two key mutagenic factors (APOBEC3 and chemotherapy) and extrachromosomal DNA-forming structural variants that…
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Nature – Whole-genome sequencing of matched serial tumours from patients identifies two key mutagenic factors (APOBEC3 and chemotherapy) and extrachromosomal DNA-forming structural variants that…